Winter cod liver oil · Original null result for reduced serious COVID-19

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Serious COVID-19, component/denominator gapsHow is the selected serious-COVID-19 claim distinguished from infection/respiratory claims?Required	The selected existing question is reduced serious COVID-19. Its subclaim record is linked; PCR infection and other acute respiratory infection remain original context. No new question, split or trial is created. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. No new certification of clinical independence was made.	Selected serious-outcome question/record and parent/infection/other respiratory endpoints	A plan distinguishing infection, serious outcomes and other respiratory results
2	Partly verified	Full text not readStored summary read	N02 · Serious COVID-19, component/denominator gapsWhat are the selected D/note and absent score/status/axes?Required	Selected D and the note “Null, RR 1.20 (0.87–1.65)” are preserved. Subclaim score/status/axes are absent; parent D with 34 points and its axes remain separate historical context. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Subclaim score/status/axes are absent from the original.	Subclaim D, RR 1.20 (0.87–1.65) and parent history	Separate original grades from new evidence/changes
3	Partly verified	Full text not readStored summary read	N03 · Serious COVID-19, component/denominator gapsWhat are the population and routine vitamin-D supplementation boundaries?Required	The original concerns winter cod liver oil in adults not taking vitamin D supplements daily and records 34,601 Norwegian adults. It does not directly establish results for deficiency treatment or every adult. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Age/sex, selection/exclusions, baseline conditions/vitamin status and infection risk remain unverified.	Norwegian adults, no routine daily supplements, selection/baseline	Research specifying the population and routine-supplement scope
4	Partly verified	Full text not readStored summary read	N04 · Serious COVID-19, component/denominator gapsWhat separates winter/the trial period from current variants, vaccination and treatment?Required	The original describes about six winter months, registration posted 2020-10-30 and start 2020-11-10. Details of variants, vaccination/previous infection and concurrent treatment are absent from the summary. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Period-specific pathogens/vaccination, previous infection, exposure/treatment and subgroups remain unverified.	Original winter period, stated 2020 start and baseline/period exposures	Research distinguishing period/population boundaries
5	Partly verified	Full text not readStored summary read	N05 · Serious COVID-19, component/denominator gapsWhat was the original combination-product exposure at 5 mL/day?Required	Original cod liver oil 5 mL/day contained vitamin D 10 µg and about 1 g of n-3 fatty acids. The original Möller’s Tran manufacturer-product description is preserved; the combination is not split into single-ingredient effects. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Composition/manufacture/quality, other ingredients and actual adherence/exposure specifications remain unverified.	Cod liver oil, vitamin D 10 µg/about 1 g n-3 and original product identity	Research specifying combination product/population exposure
6	Partly verified	Full text not readStored summary read	N06 · Serious COVID-19, component/denominator gapsWhat does the flavour-matched corn-oil comparator answer?Required	The original compares flavour-matched corn-oil placebo, 17,323 adults, with cod liver oil, 17,278. This was not a comparison with no treatment, high-dose vitamins or omega-3 alone. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Comparator composition/exposure, condition recognition/actual adherence and shared procedures remain unverified.	Original corn-oil placebo, sensory features/composition/common conditions	A plan specifying the exact comparator and estimand
7	Partly verified	Full text not readStored summary read	N07 · Serious COVID-19, component/denominator gapsHow are a median 164 days/about six months separated from actual exposure/follow-up?Required	The original records a median 164 days of use and about six winter months. Individual exposure durations, adherence/discontinuation and infection/serious-outcome follow-up times are not detailed in the summary. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Individual/arm-specific exposure, adherence/discontinuation, time at risk and outcome observation remain unverified.	Median 164 days of use, winter period, outcome observation/adherence	Research separating exposure from event-observation periods
8	Unverified	Full text not readStored summary read	N08 · Serious COVID-19, component/denominator gapsWhat is the exact serious-COVID-19 event/composite definition?Required	The original records serious COVID-19 as one coprimary outcome. Exact severity criteria, composite components/adjudication and confirmation methods are not provided in the summary. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Composite definition/components, thresholds, testing/physician adjudication and confirmation timing remain unverified.	Serious-outcome definition, confirmation, composite/components and thresholds	Research specifying the serious composite and individual components
9	Partly verified	Full text not readStored summary read	N09 · Serious COVID-19, component/denominator gapsWhat are the selected serious-outcome events, RR and adjusted interval?Required	Following the original endpoint order, serious outcomes were cod liver oil 121 versus placebo 101, RR 1.20 (0.87–1.65). Korean/English text describes adjusted 95% intervals and the original null result. No new RR/CI/P is calculated. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Whether events count people, first/repeated events or composite events, and the relevant denominator/model/adjustment method, remain unverified.	Serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65)	Research specifying estimand, events/denominators and adjustment
10	Unverified	Full text not readStored summary read	N10 · Serious COVID-19, component/denominator gapsIs hospitalization the same as the individual effect of the serious composite?Required	Original serious-event totals 121/101 and RR exist, but hospitalization components/inclusion, original events/denominators and effect/CI are not separately available. The composite result is not copied as a hospitalization result. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Hospitalization components, definition/confirmation, events/denominators/time and effect intervals remain unverified.	Hospitalization definition/confirmation, events/denominator and composite relationship	A plan distinguishing the composite from individual hospitalization outcomes
11	Unverified	Full text not readStored summary read	N11 · Serious COVID-19, component/denominator gapsIs death the same as the individual effect of the serious composite?Required	The original summary lacks individual COVID-19/all-cause-death components, events/denominators and effect/CI. The serious-outcome RR is not transferred to a mortality RR. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Cause-specific/all-cause death, composite inclusion, events/denominators/time and estimates/CI remain unverified.	Death definition/period, components/individual events and denominator	A plan separating serious composites from cause-specific/all-cause mortality
12	Partly verified	Full text not readStored summary read	N12 · Serious COVID-19, component/denominator gapsAre randomized, infected and at-risk population denominators distinguished?Required	Original randomization of 34,601 adults (17,278/17,323) is preserved. The exact serious-event risk denominator, conditional serious-outcome denominator among PCR-infected participants and risk subgroups are not separately available. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Outcome-specific effective denominators/infection conditions, time/subgroups and event aggregation remain unverified.	34,601/arm sizes versus serious-outcome/infected/event-risk denominators	Research distinguishing populations, denominators and conditional estimands
13	Partly verified	Full text not readStored summary read	N13 · Serious COVID-19, component/denominator gapsWhat is the uncertainty in serious/component events and intervals?Required	Original serious events 121/101, RR 1.20, interval 0.87–1.65 and parent C0 are preserved. A large overall sample does not guarantee precision, exclusion of small differences or equivalence for each component. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Component events/denominators, estimates/CI, power/importance and sparse-event handling remain unverified.	Original events/intervals, component sparsity/precision and importance	A plan distinguishing overall sample size from outcome-specific precision
14	Partly verified	Full text not readStored summary read	N14 · Serious COVID-19, component/denominator gapsHow are PCR infection, negative tests and other ARI different endpoints?Supplementary	Original PCR 227/228, RR 1.00 (0.82–1.22); negative tests 8,546/8,565, RR 1.00 (0.97–1.04); and self-reported ARI 3,964/3,834, RR 1.04 (0.97–1.11), are preserved as other-endpoint context. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Event definitions/confirmation, people/tests/repetition and denominators/models for each endpoint remain unverified.	Original order of four results, related outcomes, negative tests and questionnaire ARI	A plan separating infection, tests, symptoms and serious outcomes
15	Partly verified	Full text not readStored summary read	N15 · Serious COVID-19, component/denominator gapsWhat was the original scope of four coprimary outcomes, fallback and adjusted intervals?Required	The original describes all four coprimary outcomes as null and multiplicity control through prespecified fallback. Original adjusted 95% intervals are preserved; exact rules/adjustments/original plans remain externally unread. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Fallback allocation/success rules, interval/model adjustment and plan versions remain unverified.	Coprimary hierarchy, multiplicity/fallback and interval adjustment	Research specifying coprimary outcomes, estimands and multiplicity
16	Partly verified	Full text not readStored summary read	N16 · Serious COVID-19, component/denominator gapsWhat is known from the registration ID/posting/start versus current plan reading?Required	Original NCT04609423 and prospective registration posted 2020-10-30 before start 2020-11-10 are preserved. External registration, protocol and SAP were not queried/read this time. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Registration content/versions, prespecified outcomes/analyses and amendment/posting records remain unread.	NCT04609423, original 2020-10-30/11-10 and prospective description	Records preserving prespecified plans and amendment events
17	Partly verified	Full text not readStored summary read	N17 · Serious COVID-19, component/denominator gapsWhat do the original concealment/quadruple-masking quotations record?Required	The original research explanation preserves quotations on hospital research-support allocation without investigator involvement and masking of participants, researchers, care, collection, assessment and analysis personnel. Actual procedures/condition recognition were not newly reviewed externally. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Allocation/concealment, maintained masking/condition comparability and baseline-balance details remain unread.	Allocation without investigator involvement and masked participant/research/collection/assessment/analysis roles	Research specifying exact allocation and masking roles
18	Partly verified	Full text not readStored summary read	N18 · Serious COVID-19, component/denominator gapsIs 0.05% key-variable missingness the same as missing events/components?Required	Original 34,601/17,278/17,323 and 0.05% key-variable missingness are preserved. Endpoint/serious-component omissions, risk denominators and completed withdrawal/infection follow-up are not separately available. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Missingness by arm/endpoint/component, reasons for withdrawal/discontinuation and missing-data handling remain unverified.	Randomized/arm sizes, 0.05% key variables and outcome-specific denominators/flow	A plan distinguishing all participants/key variables from outcome-specific completeness
19	Partly verified	Full text not readStored summary read	N19 · Serious COVID-19, component/denominator gapsWhat separates original ITT from adherence/infection-conditioned estimands?Required	The original records an ITT quotation for all randomized participants. Adherer/infection-conditioned analyses, actual exposure and model/adjustment/missing-data details are absent from the summary. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Estimands/analysis populations, adherence/missingness and covariate/conditional models remain unverified.	All randomized adults in ITT, actual exposure/infected participants and serious-outcome estimand	A plan distinguishing assigned prevention effects from serious-outcome effects among infected participants
20	Unverified	Full text not readStored summary read	N20 · Serious COVID-19, component/denominator gapsWere baseline vitamins/conditions, vaccination and concurrent exposures verified?Required	The original specifies no routine daily supplements and the winter/combination-product scope. Baseline vitamin status, comorbidities/medications, vaccination/exposure and other supplement/treatment details are absent. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Baseline/changed conditions/medications, supplements/vaccination/infection exposures and arm differences remain unverified.	Baseline/medications, other supplements/exposures and arm differences	Research specifying population and shared exposures
21	Partly verified	Full text not readStored summary read	N21 · Serious COVID-19, component/denominator gapsWhat are the original manufacturer/institution support and outside/diagnostics-author relationships?Required	The original records Orkla Health AS funding/products/placebo, Oslo hospital/university support, KBH’s outside relationships with Olympic Seafood/Amgen/Sanofi, SMU’s with Olympic Seafood, and AS/KTK employment at Age Laboratories. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Original disclosures/supporters and current design/analysis/data-access role details remain unread.	Orkla supply/funding, Oslo support and disclosed relationships/employees	Specify funding and research-decision/analysis roles
22	Partly verified	Full text not readStored summary read	N22 · Serious COVID-19, component/denominator gapsHow are the same trial/people/composite components and related claims connected?Required	The existing single evidence/citation report links four outcomes, the same people/arms/period and related claims. Composite components, tests/symptoms/events are not added as new independent trials/participants. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Individual overlap/component relationships, related reports and unique-trial/participant totals remain unverified.	Single Brunvoll 2022 citation, four outcomes/arms/period and overlap	Records distinguishing reports from trial families/components
23	Unverified	Full text not readStored summary read	N23 · Serious COVID-19, component/denominator gapsWhat separates direct independent serious-outcome confirmation from the single-trial history?Required	Parent R1/I0 and the single large manufacturer-supported trial description are preserved as history. Other independent serious-outcome source materials were not newly searched for/acquired. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Populations/products/serious-outcome definitions and overlap/independence in separate direct reports remain unverified.	Selected product/population and independent reports of the same serious outcome	Separate research specifying the same product/population/serious-outcome definition
24	Partly verified	Full text not readStored summary read	N24 · Serious COVID-19, component/denominator gapsWhat separates a null combination product from deficiency/high-dose/single-ingredient effects?Supplementary	Original counterview/ad interpretation explicitly excludes deficiency treatment, high-dose vitamin D and omega-3 alone. Combination-product results are not turned into individual-ingredient conclusions. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Direct serious-outcome data for single/other exposures or deficient/at-risk populations remain unverified.	Original product versus deficiency treatment/high-dose vitamin D/n-3 alone	A plan separating the combination product from other questions
25	Partly verified	Full text not readStored summary read	N25 · Serious COVID-19, component/denominator gapsWhich serious, hospitalization/death, symptom/quality-of-life outcomes can be answered?Supplementary	Original serious-event totals and infection/questionnaire ARI are different outcomes. Direct values for individual hospitalization/death, quality of life/symptom severity or treating serious disease after infection are not separately available. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Clinical components/important outcomes and direct definitions/denominators/effects/periods remain unverified.	Original serious-outcome name, individual/patient-important outcomes and treatment questions	Research distinguishing prevention/serious outcomes/treatment and component-specific estimands
26	Partly verified	Full text not readStored summary read	N26 · Serious COVID-19, component/denominator gapsWhat is the scope of summary reading, unread external materials and original links?Required	The entire preserved 2972 summary was read and saved for production. PubMed URL/NCT are original source links; external content/link access, clicks and tests were not performed. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Current verification of external serious-outcome definitions/methods/results and registration/plan/disclosure details remains incomplete.	Entire summary, abstract/full text/registration/plans/disclosures	Records separating summaries/identities from new acquisition
27	Partly verified	Full text not readStored summary read	N27 · Serious COVID-19, component/denominator gapsWhat are the bilingual text, dates/corrections, original axes/absences and history?Required	Bilingual text, original evidence date 2026-08-26 and empty corrections/deliberation are preserved. Parent B/H/R1/I0/E0/B0/C0, the true large-hard-endpoint-RCT indicator, two false indicators and empty grade-override reasons remain historical context. Separate classification fields and the primary-failed/secondary-positive indicator are unrecorded. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. External original quotations/translations and detailed registration/correction comparisons were not performed this time.	Parent D with 34 points, languages/dates/empty values and B0 quotations/axes	Separate original values/absences from new updates
28	Partly verified	Full text not readStored summary read	N28 · Serious COVID-19, component/denominator gapsWhat was the original scope of harm collection and low-grade side effects?Supplementary	The original safety description states that only low-grade side effects were reported in both arms. All event definitions, collection/grading methods and serious/related-event/arm-count details are absent from the summary. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Harm collection/grading, all events and original causality/discontinuation tables remain unverified.	Side-effect definitions/grading, collection/causality and arm events	Research specifying harm collection separately from efficacy
29	Partly verified	Full text not readStored summary read	N29 · Serious COVID-19, component/denominator gapsAre side effects, serious COVID-19 and hospitalization/death categories distinguished?Supplementary	The serious-COVID-19 RR and low-grade side-effect descriptions in both arms concern different outcomes. Serious-event counts 121/101 are not transferred to product-side-effect counts. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Definitions, causality/components and denominators for efficacy events/exposure harms remain unverified.	Exposure harms, trial-efficacy serious outcomes and other-event causality	A plan separating infection severity from exposure harms
30	Unverified	Full text not readStored summary read	N30 · Serious COVID-19, component/denominator gapsAre overall/arm-specific harm denominators the same as key-variable missingness?Supplementary	Randomized arm sizes and key-variable missingness are described, but collection/denominators/exposure time and CI for each side effect are not separately available. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Harm denominators by arm/event/period and comparative effects/CI remain unverified.	17,278/17,323, key-variable 0.05% and harm-observation populations	Research distinguishing efficacy analyses from harm-observation populations
31	Unverified	Full text not readStored summary read	N31 · Serious COVID-19, component/denominator gapsWhat is known about harm timing, after stopping, delayed and long-term observation?Supplementary	The original has a median 164 days of use and low-grade descriptions in both arms, but no side-effect timing or post-discontinuation/delayed/longer observation details. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Exposure/event timing and direct post-study/long-term harms remain unverified.	Original median 164 days and side-effect timing/exposure/follow-up	A plan distinguishing timing and delayed harms
32	Unverified	Full text not readStored summary read	N32 · Serious COVID-19, component/denominator gapsWhat alternative causes involve combination product/placebo, medical history and medications?Supplementary	The original product is a combination and placebo flavour-matched corn oil. Detailed source materials attributing events to product/individual ingredients, baseline status or concurrent medications are absent. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Baseline/concurrent medications, actual exposure and event-specific causality/alternative causes remain unverified.	Vitamin/n-3 combination, shared exposures and event causality	A harm plan distinguishing relevant exposure from alternative causes
33	Unverified	Full text not readStored summary read	N33 · Serious COVID-19, component/denominator gapsAre key-variable missingness, serious-outcome confirmation and harm-related stopping distinguished?Supplementary	Original 0.05% key-variable missingness and ITT are preserved. Serious-event confirmation/component omissions, side-effect-related stopping and complete harm collection are not detailed. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Event/harm omissions, arm-specific stopping reasons/causality and handling remain unverified.	0.05% missingness, event confirmation/collection and stopping reasons	A plan distinguishing missing efficacy data from harm-related stopping
34	Unverified	Full text not readStored summary read	N34 · Serious COVID-19, component/denominator gapsHow do independent harm materials differ from the same trial/components/related claims?Supplementary	The current list contains this large efficacy report. Separate original harm materials were not newly searched for/acquired; the same trial/people, composite components and related claims are not counted as independent harm trials. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Independent harm-material identities, population/product/exposure and overlap remain unverified.	Separate safety-material identities and overlap in the same people/components	Records distinguishing the same trial from independent harms
35	Unverified	Full text not readStored summary read	N35 · Serious COVID-19, component/denominator gapsWhat are the boundaries for deficient/at-risk/vulnerable populations, current periods and long-term safety?Supplementary	The original limits scope to the tested dose/participants. It does not judge direct safety in deficient/high-risk/other-condition populations, current periods, long-term exposure or different products. R01	Required direct materials were not verified within the current summary/unread-external-material scope. Direct events, medications and long-term follow-up by population/period/exposure remain unverified.	Original winter product/population versus other risks/exposures/periods	Research separating population and long-term safety questions
36	Partly verified	Full text not readStored summary read	N36 · Serious COVID-19, component/denominator gapsAre the causal scopes of null serious outcomes, other endpoints and good safety separated?Supplementary	Original null serious outcomes, null findings for the other three endpoints, low-grade side effects and parent good safety are preserved separately. The serious-outcome interval/null result is not confirmed harm, equivalence/no-harm certification or separate hospitalization/death conclusions. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Direct component/comparative harms, causality/importance and long-term precision remain unverified.	Serious-outcome RR/interval, efficacy/harms and parent safety	A plan separating different estimands/outcomes
37	Partly verified	Full text not readStored summary read	N37 · Serious COVID-19, component/denominator gapsHow are follow-up materials, historical candidates, versions and incomplete content review linked?Supplementary	Conditions were preserved/frozen before separate application. Candidate review-pending/production-eligibility labels remain historical records; current content/question-boundary review is incomplete. Zero new units and unrecorded confirmed independent totals are retained. R01	Some original summary information is linked for production; this does not establish clinical verification/completed content review. Follow-up original materials, actual reading, changes, content review and independence decisions do not yet exist.	Preserved summary, conditions, units, denominators, components, original values and addition events	Research addressing direct gaps in the selected serious-COVID-19 question

No items match your search or filter.

37 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Norwegian adults not taking vitamin D supplements daily; original 34,601 randomized; direct serious-outcome risk/infected-population denominators unverified
Ingredient, formulation and route: Winter cod liver oil 5 mL/day in adults not taking vitamin D supplements daily
Dose: Original combination-study exposure preserved: cod liver oil 5 mL/day, vitamin D 10 µg/about 1 g n-3; no intake/conversion/management guidance
Comparator: Flavour-matched corn-oil placebo; original randomized arm sizes 17,278/17,323
Measured outcome: Selected serious COVID-19: original 121/101, RR 1.20/interval 0.87–1.65; exact composite/components/confirmation/denominator unverified
Duration: Original about six winter months, median 164 days of use; distinguished from individual/event/risk periods, long-term follow-up and treatment scope
Questions outside this scope: Repurposing serious events 121/101/RR as individual hospitalization/death components or treatment after infection; Adding PCR/negative tests/ARI or related claims as serious outcomes or independent trials; Copying full arm sizes/infection events as every risk-population/component denominator; Extending a null combination product to deficiency/high-dose/single ingredients, all current periods or treatment; Cod-liver-oil/vitamin/product-use, infection-prevention/COVID-19 management/serious-disease treatment or treatment-replacement instructions

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Brunvoll SH, et al. Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation. BMJ. 2022;378:e071245. PMID: 36215222.

PubMed

Material type: Brunvoll 2022 winter cod-liver-oil report: selected serious outcome among four coprimary endpoints, with other results preserved
Materials actually read: Summary read; external materials unread, access not attempted
Findings recorded in the stored summary: Original serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65); the other three endpoints remain separate context in the full original evidence-result record.
Record level: Selected original serious-outcome RR/adjusted 95% interval and null result. Exact serious composite/components, hospitalization/death/confirmation/risk denominators unverified. A preventive assignment trial is not repurposed as treatment effects after infection.
Study overlap and independent replication: Brunvoll 2022 links the same trial/citation, two assigned arms, four endpoints/serious components, people/period and parent/PCR/serious/other-respiratory claims. No new totals of independent trials/participants/events.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Local preserved summary	Summary read	Summary read	Only acquisition/reading of the entire parent summary. Original paper/registration or serious-component result tables were not acquired.
Abstract	External materials unread/needed	Unread; access not attempted	Not read	Only the original citation URL is linked. External content/access and link tests were not attempted.
Full paper	External materials unread/needed	Unread; access not attempted	Not read	Original DOI/PMCID not provided. No new acquisition/reading of the full text/content.
Registration material	External materials unread/needed	Unread; access not attempted	Not read	NCT04609423 and original posting/start/prospective descriptions preserved. Actual versions/content unread.
Protocol	External materials unread/needed	Unread; access not attempted	Not read	Original plans for product/population, serious composite/components/confirmation, risk denominators, four primary outcomes and harms are needed. Existence/publication status unverified.
Statistical analysis plan	External materials unread/needed	Unread; access not attempted	Not read	Original plans for ITT/at-risk populations, RR/intervals, fallback/adjustment and sparse-event/missingness/component analyses are needed.
Result tables and serious-component/denominator/harm materials	External materials unread/needed	Unread; access not attempted	Not read	Details needed for serious events 121/101/original RR, components/infected/at-risk populations, repetition/omissions and harms. No new event/CI calculation.
Funding/conflict-of-interest disclosures	External materials unread/needed	Unread; access not attempted	Not read	Original disclosures on Orkla/Oslo support, products/placebo, outside relationships/diagnostics-company employees and roles are currently unread.

Report counts versus independent study counts

Brunvoll 2022 links the same trial/citation, two assigned arms, four endpoints/serious components, people/period and parent/PCR/serious/other-respiratory claims. No new totals of independent trials/participants/events.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · How is the selected serious-COVID-19 claim distinguished from infection/respiratory claims?

Required materials and conditions: Selected serious-outcome question/record and parent/infection/other respiratory endpoints
Conditions for verification: For Selected serious-outcome question/record and parent/infection/other respiratory endpoints, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not repurpose PCR/symptom results as direct effects on the selected serious outcome or add new related units.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How is the selected serious-COVID-19 claim distinguished from infection/respiratory claims?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M03 §3.2.4; Custom extension boundary

N02 · What are the selected D/note and absent score/status/axes?

Required materials and conditions: Subclaim D, RR 1.20 (0.87–1.65) and parent history
Conditions for verification: For Subclaim D, RR 1.20 (0.87–1.65) and parent history, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not repurpose parent 34 points or H/E0/C0/B0 axes as subclaim values or current clinical review/efficacy certification.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the selected D/note and absent score/status/axes?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N03 · What are the population and routine vitamin-D supplementation boundaries?

Required materials and conditions: Norwegian adults, no routine daily supplements, selection/baseline
Conditions for verification: For Norwegian adults, no routine daily supplements, selection/baseline, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not extend to deficiency treatment, specific risk groups/every adult or intake guidance.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the population and routine vitamin-D supplementation boundaries?
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

N04 · What separates winter/the trial period from current variants, vaccination and treatment?

Required materials and conditions: Original winter period, stated 2020 start and baseline/period exposures
Conditions for verification: For Original winter period, stated 2020 start and baseline/period exposures, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not newly establish the winter result for all current variants/vaccination states or serious-COVID-19 treatment efficacy.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates winter/the trial period from current variants, vaccination and treatment?
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application

N05 · What was the original combination-product exposure at 5 mL/day?

Required materials and conditions: Cod liver oil, vitamin D 10 µg/about 1 g n-3 and original product identity
Conditions for verification: For Cod liver oil, vitamin D 10 µg/about 1 g n-3 and original product identity, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: No new dose conversion, cod-liver-oil/vitamin/product-use instructions, ingredient recommendations or treatment methods.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original combination-product exposure at 5 mL/day?
Referenced methods: M03 §§3.2.2–3.2.3; reverse-direction labels and assessment adaptation are Chamgap-designed; M03 §§3.2.1–3.2.4; dose, durability and effect-modification details are Chamgap-designed

N06 · What does the flavour-matched corn-oil comparator answer?

Required materials and conditions: Original corn-oil placebo, sensory features/composition/common conditions
Conditions for verification: For Original corn-oil placebo, sensory features/composition/common conditions, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not turn the combination-product comparison into new superiority claims for single ingredients, all products or other treatments.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What does the flavour-matched corn-oil comparator answer?
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.1–8.2.3; internal application

N07 · How are a median 164 days/about six months separated from actual exposure/follow-up?

Required materials and conditions: Median 164 days of use, winter period, outcome observation/adherence
Conditions for verification: For Median 164 days of use, winter period, outcome observation/adherence, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not calculate 164 days as a fixed duration for everyone, total product amounts or person-time, or provide an intake schedule.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are a median 164 days/about six months separated from actual exposure/follow-up?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N08 · What is the exact serious-COVID-19 event/composite definition?

Required materials and conditions: Serious-outcome definition, confirmation, composite/components and thresholds
Conditions for verification: For Serious-outcome definition, confirmation, composite/components and thresholds, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not newly define severity using hospitalization/death alone or add symptoms/components absent from the original.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the exact serious-COVID-19 event/composite definition?
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

N09 · What are the selected serious-outcome events, RR and adjusted interval?

Required materials and conditions: Serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65)
Conditions for verification: For Serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65), separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not turn RR>1 into confirmed harm/a significant increase or certify the original null result as exactly zero effect/equivalence.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the selected serious-outcome events, RR and adjusted interval?
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application; M15 §15.3.1–15.3.3; Chamgap application

N10 · Is hospitalization the same as the individual effect of the serious composite?

Required materials and conditions: Hospitalization definition/confirmation, events/denominator and composite relationship
Conditions for verification: For Hospitalization definition/confirmation, events/denominator and composite relationship, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not transfer 121/101 to hospitalization counts or create zero hospitalizations or reduction/increase effects.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is hospitalization the same as the individual effect of the serious composite?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.4; internal extension boundaries

N11 · Is death the same as the individual effect of the serious composite?

Required materials and conditions: Death definition/period, components/individual events and denominator
Conditions for verification: For Death definition/period, components/individual events and denominator, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not add zero deaths or sparse-event counts absent from the original, or judge null serious outcomes as mortality equivalence/no harm.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is death the same as the individual effect of the serious composite?
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.4; internal extension boundaries

N12 · Are randomized, infected and at-risk population denominators distinguished?

Required materials and conditions: 34,601/arm sizes versus serious-outcome/infected/event-risk denominators
Conditions for verification: For 34,601/arm sizes versus serious-outcome/infected/event-risk denominators, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not use PCR 227/228 as serious-outcome denominators or copy full arm sizes to every component/subgroup.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are randomized, infected and at-risk population denominators distinguished?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.1; detailed population conditions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

N13 · What is the uncertainty in serious/component events and intervals?

Required materials and conditions: Original events/intervals, component sparsity/precision and importance
Conditions for verification: For Original events/intervals, component sparsity/precision and importance, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not calculate new P/CI where original intervals/P are absent or newly conclude that all important benefits/harms are excluded.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the uncertainty in serious/component events and intervals?
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

N14 · How are PCR infection, negative tests and other ARI different endpoints?

Required materials and conditions: Original order of four results, related outcomes, negative tests and questionnaire ARI
Conditions for verification: For Original order of four results, related outcomes, negative tests and questionnaire ARI, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not turn negative tests into other confirmed infections or sum the four event counts/related claims into serious outcomes or independent trials.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are PCR infection, negative tests and other ARI different endpoints?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.4; internal extension boundaries

N15 · What was the original scope of four coprimary outcomes, fallback and adjusted intervals?

Required materials and conditions: Coprimary hierarchy, multiplicity/fallback and interval adjustment
Conditions for verification: For Coprimary hierarchy, multiplicity/fallback and interval adjustment, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not create current prospective-specification certification from four endpoint names/original B0 quotations or arbitrarily interpret interval adjustment as baseline-covariate adjustment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original scope of four coprimary outcomes, fallback and adjusted intervals?
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M15 §15.3.1–15.3.3; internal application

N16 · What is known from the registration ID/posting/start versus current plan reading?

Required materials and conditions: NCT04609423, original 2020-10-30/11-10 and prospective description
Conditions for verification: For NCT04609423, original 2020-10-30/11-10 and prospective description, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not upgrade original prospective/matching quotations to current registration verification or completed plan review, or calculate date differences.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is known from the registration ID/posting/start versus current plan reading?
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N17 · What do the original concealment/quadruple-masking quotations record?

Required materials and conditions: Allocation without investigator involvement and masked participant/research/collection/assessment/analysis roles
Conditions for verification: For Allocation without investigator involvement and masked participant/research/collection/assessment/analysis roles, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not inherit original B0/quadruple masking as current completed risk-of-bias/content review or independence certification.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What do the original concealment/quadruple-masking quotations record?
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N18 · Is 0.05% key-variable missingness the same as missing events/components?

Required materials and conditions: Randomized/arm sizes, 0.05% key variables and outcome-specific denominators/flow
Conditions for verification: For Randomized/arm sizes, 0.05% key variables and outcome-specific denominators/flow, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not convert 0.05% to a person count or copy it to missingness rates for every endpoint/harm.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is 0.05% key-variable missingness the same as missing events/components?
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is our own design; M08 §8.2.2, M15 §15.3.1; own application; M19 §19.1.2–19.2.4, M04 §4.6.3; own application

N19 · What separates original ITT from adherence/infection-conditioned estimands?

Required materials and conditions: All randomized adults in ITT, actual exposure/infected participants and serious-outcome estimand
Conditions for verification: For All randomized adults in ITT, actual exposure/infected participants and serious-outcome estimand, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not repurpose a preventive assignment trial’s serious-outcome RR as treatment after infection or newly calculate absent denominators.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates original ITT from adherence/infection-conditioned estimands?
Referenced methods: M08 §8.2.2, M15 §15.3.1; own application; M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M08 Table 8.2.a, M04 §4.6.3; own application

N20 · Were baseline vitamins/conditions, vaccination and concurrent exposures verified?

Required materials and conditions: Baseline/medications, other supplements/exposures and arm differences
Conditions for verification: For Baseline/medications, other supplements/exposures and arm differences, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not add deficiency diagnoses, high-dose/single-ingredient effects or infection-prevention/treatment methods without original materials.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Were baseline vitamins/conditions, vaccination and concurrent exposures verified?
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1; detailed population conditions are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed

N21 · What are the original manufacturer/institution support and outside/diagnostics-author relationships?

Required materials and conditions: Orkla supply/funding, Oslo support and disclosed relationships/employees
Conditions for verification: For Orkla supply/funding, Oslo support and disclosed relationships/employees, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not combine diagnostics-company employees with manufacturer employees or turn manufacturer null reporting into independence/content-review certification or invalidation of the numbers.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the original manufacturer/institution support and outside/diagnostics-author relationships?
Referenced methods: Chamgap’s own independence/attribution conditions. The official methodological sections used in this pilot do not guarantee every detailed item; M08 §8.1–8.2.3; internal application

N22 · How are the same trial/people/composite components and related claims connected?

Required materials and conditions: Single Brunvoll 2022 citation, four outcomes/arms/period and overlap
Conditions for verification: For Single Brunvoll 2022 citation, four outcomes/arms/period and overlap, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: One report or four outcomes do not certify the total independent-trial count or final independence count.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are the same trial/people/composite components and related claims connected?
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N23 · What separates direct independent serious-outcome confirmation from the single-trial history?

Required materials and conditions: Selected product/population and independent reports of the same serious outcome
Conditions for verification: For Selected product/population and independent reports of the same serious outcome, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not extend the original single trial into a current claim of no worldwide studies or count related outcomes as independent replication.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates direct independent serious-outcome confirmation from the single-trial history?
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N24 · What separates a null combination product from deficiency/high-dose/single-ingredient effects?

Required materials and conditions: Original product versus deficiency treatment/high-dose vitamin D/n-3 alone
Conditions for verification: For Original product versus deficiency treatment/high-dose vitamin D/n-3 alone, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: No new vitamin-use/deficiency-treatment guidance, product/ingredient recommendations or high-dose/treatment-replacement methods.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates a null combination product from deficiency/high-dose/single-ingredient effects?
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed

N25 · Which serious, hospitalization/death, symptom/quality-of-life outcomes can be answered?

Required materials and conditions: Original serious-outcome name, individual/patient-important outcomes and treatment questions
Conditions for verification: For Original serious-outcome name, individual/patient-important outcomes and treatment questions, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not extend the original prevention null result to current serious-disease treatment failure or alternative-treatment selection.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Which serious, hospitalization/death, symptom/quality-of-life outcomes can be answered?
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

N26 · What is the scope of summary reading, unread external materials and original links?

Required materials and conditions: Entire summary, abstract/full text/registration/plans/disclosures
Conditions for verification: For Entire summary, abstract/full text/registration/plans/disclosures, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Preserve absent DOI/PMCID and unread status; a URL/ID alone does not establish acquisition or access success/failure.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the scope of summary reading, unread external materials and original links?
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N27 · What are the bilingual text, dates/corrections, original axes/absences and history?

Required materials and conditions: Parent D with 34 points, languages/dates/empty values and B0 quotations/axes
Conditions for verification: For Parent D with 34 points, languages/dates/empty values and B0 quotations/axes, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Required
Application exceptions: Do not inherit B0/prespecification/ITT quotations or cross-checking as current clinical-content review or independence certification.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the bilingual text, dates/corrections, original axes/absences and history?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M04 §4.5, §4.6.3; current material-conversion limits follow review scope and internal design; Chamgap’s own independence/attribution conditions. The official methodological sections used in this pilot do not guarantee every detailed item

N28 · What was the original scope of harm collection and low-grade side effects?

Required materials and conditions: Side-effect definitions/grading, collection/causality and arm events
Conditions for verification: For Side-effect definitions/grading, collection/causality and arm events, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not turn the original low-grade-only description into zero side effects, long-term no harm or equivalent safety.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original scope of harm collection and low-grade side effects?
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

N29 · Are side effects, serious COVID-19 and hospitalization/death categories distinguished?

Required materials and conditions: Exposure harms, trial-efficacy serious outcomes and other-event causality
Conditions for verification: For Exposure harms, trial-efficacy serious outcomes and other-event causality, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not make new product-caused-harm or guaranteed-safety verdicts from RR 1.20 or low-grade descriptions.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are side effects, serious COVID-19 and hospitalization/death categories distinguished?
Referenced methods: M19 §19.1.2–19.2.4; detailed discrimination is internally designed; Chamgap’s own interpretation boundaries. M19 principles are referenced; no official causality tool was run; M03 §3.2.4; internal extension boundaries

N30 · Are overall/arm-specific harm denominators the same as key-variable missingness?

Required materials and conditions: 17,278/17,323, key-variable 0.05% and harm-observation populations
Conditions for verification: For 17,278/17,323, key-variable 0.05% and harm-observation populations, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not copy all-participant/0.05% information into complete harm observation or calculate new incidence/differences/CI.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are overall/arm-specific harm denominators the same as key-variable missingness?
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application; M19 §19.1.2–19.2.4; internal application

N31 · What is known about harm timing, after stopping, delayed and long-term observation?

Required materials and conditions: Original median 164 days and side-effect timing/exposure/follow-up
Conditions for verification: For Original median 164 days and side-effect timing/exposure/follow-up, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not convert winter exposure into confirmed safety for all long-term/repeated use.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is known about harm timing, after stopping, delayed and long-term observation?
Referenced methods: M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; M19 §19.1.2–19.2.4; internal application

N32 · What alternative causes involve combination product/placebo, medical history and medications?

Required materials and conditions: Vitamin/n-3 combination, shared exposures and event causality
Conditions for verification: For Vitamin/n-3 combination, shared exposures and event causality, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not add unreported ingredients/invented harms or new medication/product stopping/substitution/management instructions.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What alternative causes involve combination product/placebo, medical history and medications?
Referenced methods: M19 §19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap design; M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

N33 · Are key-variable missingness, serious-outcome confirmation and harm-related stopping distinguished?

Required materials and conditions: 0.05% missingness, event confirmation/collection and stopping reasons
Conditions for verification: For 0.05% missingness, event confirmation/collection and stopping reasons, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not declare zero omissions in all harms/components from a small key-variable missingness rate or fill unverified events with zero.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are key-variable missingness, serious-outcome confirmation and harm-related stopping distinguished?
Referenced methods: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application

N34 · How do independent harm materials differ from the same trial/components/related claims?

Required materials and conditions: Separate safety-material identities and overlap in the same people/components
Conditions for verification: For Separate safety-material identities and overlap in the same people/components, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not extend the current absence of a separate slot into a claim that all external safety materials are absent.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How do independent harm materials differ from the same trial/components/related claims?
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

N35 · What are the boundaries for deficient/at-risk/vulnerable populations, current periods and long-term safety?

Required materials and conditions: Original winter product/population versus other risks/exposures/periods
Conditions for verification: For Original winter product/population versus other risks/exposures/periods, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: No new cod-liver-oil/vitamin/product-use, infection-prevention/COVID-19 management or serious-COVID-19 treatment guidance.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the boundaries for deficient/at-risk/vulnerable populations, current periods and long-term safety?
Referenced methods: M19 §19.1.2–19.2.4; internal application; M03 §3.2.1; detailed population conditions are internally designed; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed

N36 · Are the causal scopes of null serious outcomes, other endpoints and good safety separated?

Required materials and conditions: Serious-outcome RR/interval, efficacy/harms and parent safety
Conditions for verification: For Serious-outcome RR/interval, efficacy/harms and parent safety, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not turn the original product null result into null effects for all vitamins/treatment replacement, guaranteed safety or a new grade.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are the causal scopes of null serious outcomes, other endpoints and good safety separated?
Referenced methods: Chamgap’s own interpretation boundaries. M19 principles are referenced; no official causality tool was run; M03 §3.2.4; internal extension boundaries; M15 §15.3.1–15.3.3; internal application

N37 · How are follow-up materials, historical candidates, versions and incomplete content review linked?

Required materials and conditions: Preserved summary, conditions, units, denominators, components, original values and addition events
Conditions for verification: For Preserved summary, conditions, units, denominators, components, original values and addition events, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Requirement and applicability: Supplementary
Application exceptions: Do not invent current completed clinical-content review/publication from historical cross-checking or original production completion.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are follow-up materials, historical candidates, versions and incomplete content review linked?
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M04 §4.5, §4.6.3; current material-conversion limits follow review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

What the statuses mean

Met: The original content has been reviewed as meeting the conditions. This status is not used in this preparation.
Partly verified: Some information in the stored summary was linked during preparation; clinical verification or review is not complete.
Unverified: Required direct values, definitions or materials have not been established within the current storage and reading scope. This does not mean zero effect, no papers or failed access.
Review incomplete: Review of existing content or actual review incomplete.
Not reported: Used only when original materials were actually read and the outcome was judged unreported. Not used for external materials unread in this work.
Inaccessible: Used only when an actual access attempt has a recorded failure. Not used for access that was not attempted in this work.
Insufficient evidence for the conditions: Indicates insufficient direct materials for the relevant scope or conditions; it is not a new grade.
Not applicable: Used when the reason it does not apply to the original question is stated.
Conflicting data: Retains the scope of conflicting statements in original materials; it is not an arbitrary reassessment.

Change history

2026-10-14 · Public page/material version 1.0

Public-facing pages and materials were prepared from the existing 37 items. No new clinical search, verification-status changes or scoring.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · How is the selected serious-COVID-19 claim distinguished from infection/respiratory claims?

Current findings: The selected existing question is reduced serious COVID-19. Its subclaim record is linked; PCR infection and other acute respiratory infection remain original context. No new question, split or trial is created.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. No new certification of clinical independence was made.
Reason for missing information: No new certification of clinical independence was made.
Required materials and conditions: Selected serious-outcome question/record and parent/infection/other respiratory endpoints
Materials to obtain first: Original question/event definitions, population/comparator and scope-change records
Further research: A plan distinguishing infection, serious outcomes and other respiratory results
Remaining uncertainty: No new certification of clinical independence was made.
Conditions for verification: For Selected serious-outcome question/record and parent/infection/other respiratory endpoints, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How is the selected serious-COVID-19 claim distinguished from infection/respiratory claims?
Application exceptions: Do not repurpose PCR/symptom results as direct effects on the selected serious outcome or add new related units.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 principles for clarifying questions; Detailed separation rules are a custom design; M04 §4.6.1–4.6.2 distinction between studies and reports; Cohort/outcome linkage is a custom application; M03 §3.2.4; Custom extension boundary

Related sources R01

N02 · What are the selected D/note and absent score/status/axes?

Current findings: Selected D and the note “Null, RR 1.20 (0.87–1.65)” are preserved. Subclaim score/status/axes are absent; parent D with 34 points and its axes remain separate historical context.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Subclaim score/status/axes are absent from the original.
Reason for missing information: Subclaim score/status/axes are absent from the original.
Required materials and conditions: Subclaim D, RR 1.20 (0.87–1.65) and parent history
Materials to obtain first: Original subclaim and explicit change events
Further research: Separate original grades from new evidence/changes
Remaining uncertainty: Subclaim score/status/axes are absent from the original.
Conditions for verification: For Subclaim D, RR 1.20 (0.87–1.65) and parent history, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the selected D/note and absent score/status/axes?
Application exceptions: Do not repurpose parent 34 points or H/E0/C0/B0 axes as subclaim values or current clinical review/efficacy certification.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01

N03 · What are the population and routine vitamin-D supplementation boundaries?

Current findings: The original concerns winter cod liver oil in adults not taking vitamin D supplements daily and records 34,601 Norwegian adults. It does not directly establish results for deficiency treatment or every adult.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Age/sex, selection/exclusions, baseline conditions/vitamin status and infection risk remain unverified.
Reason for missing information: Age/sex, selection/exclusions, baseline conditions/vitamin status and infection risk remain unverified.
Required materials and conditions: Norwegian adults, no routine daily supplements, selection/baseline
Materials to obtain first: Selection criteria and baseline/vitamin-status tables
Further research: Research specifying the population and routine-supplement scope
Remaining uncertainty: Age/sex, selection/exclusions, baseline conditions/vitamin status and infection risk remain unverified.
Conditions for verification: For Norwegian adults, no routine daily supplements, selection/baseline, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the population and routine vitamin-D supplementation boundaries?
Application exceptions: Do not extend to deficiency treatment, specific risk groups/every adult or intake guidance.
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application

Related sources R01

N04 · What separates winter/the trial period from current variants, vaccination and treatment?

Current findings: The original describes about six winter months, registration posted 2020-10-30 and start 2020-11-10. Details of variants, vaccination/previous infection and concurrent treatment are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Period-specific pathogens/vaccination, previous infection, exposure/treatment and subgroups remain unverified.
Reason for missing information: Period-specific pathogens/vaccination, previous infection, exposure/treatment and subgroups remain unverified.
Required materials and conditions: Original winter period, stated 2020 start and baseline/period exposures
Materials to obtain first: Actual period/baseline exposures and pathogen/treatment data
Further research: Research distinguishing period/population boundaries
Remaining uncertainty: Period-specific pathogens/vaccination, previous infection, exposure/treatment and subgroups remain unverified.
Conditions for verification: For Original winter period, stated 2020 start and baseline/period exposures, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates winter/the trial period from current variants, vaccination and treatment?
Application exceptions: Do not newly establish the winter result for all current variants/vaccination states or serious-COVID-19 treatment efficacy.
Referenced methods: M03 §3.2.1; detailed population conditions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application

Related sources R01

N05 · What was the original combination-product exposure at 5 mL/day?

Current findings: Original cod liver oil 5 mL/day contained vitamin D 10 µg and about 1 g of n-3 fatty acids. The original Möller’s Tran manufacturer-product description is preserved; the combination is not split into single-ingredient effects.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Composition/manufacture/quality, other ingredients and actual adherence/exposure specifications remain unverified.
Reason for missing information: Composition/manufacture/quality, other ingredients and actual adherence/exposure specifications remain unverified.
Required materials and conditions: Cod liver oil, vitamin D 10 µg/about 1 g n-3 and original product identity
Materials to obtain first: Study-product specifications and actual exposure/adherence records
Further research: Research specifying combination product/population exposure
Remaining uncertainty: Composition/manufacture/quality, other ingredients and actual adherence/exposure specifications remain unverified.
Conditions for verification: For Cod liver oil, vitamin D 10 µg/about 1 g n-3 and original product identity, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original combination-product exposure at 5 mL/day?
Application exceptions: No new dose conversion, cod-liver-oil/vitamin/product-use instructions, ingredient recommendations or treatment methods.
Referenced methods: M03 §§3.2.2–3.2.3; reverse-direction labels and assessment adaptation are Chamgap-designed; M03 §§3.2.1–3.2.4; dose, durability and effect-modification details are Chamgap-designed

Related sources R01

N06 · What does the flavour-matched corn-oil comparator answer?

Current findings: The original compares flavour-matched corn-oil placebo, 17,323 adults, with cod liver oil, 17,278. This was not a comparison with no treatment, high-dose vitamins or omega-3 alone.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Comparator composition/exposure, condition recognition/actual adherence and shared procedures remain unverified.
Reason for missing information: Comparator composition/exposure, condition recognition/actual adherence and shared procedures remain unverified.
Required materials and conditions: Original corn-oil placebo, sensory features/composition/common conditions
Materials to obtain first: Active/placebo specifications and masking/adherence data
Further research: A plan specifying the exact comparator and estimand
Remaining uncertainty: Comparator composition/exposure, condition recognition/actual adherence and shared procedures remain unverified.
Conditions for verification: For Original corn-oil placebo, sensory features/composition/common conditions, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What does the flavour-matched corn-oil comparator answer?
Application exceptions: Do not turn the combination-product comparison into new superiority claims for single ingredients, all products or other treatments.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.1–8.2.3; internal application

Related sources R01

N07 · How are a median 164 days/about six months separated from actual exposure/follow-up?

Current findings: The original records a median 164 days of use and about six winter months. Individual exposure durations, adherence/discontinuation and infection/serious-outcome follow-up times are not detailed in the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Individual/arm-specific exposure, adherence/discontinuation, time at risk and outcome observation remain unverified.
Reason for missing information: Individual/arm-specific exposure, adherence/discontinuation, time at risk and outcome observation remain unverified.
Required materials and conditions: Median 164 days of use, winter period, outcome observation/adherence
Materials to obtain first: Exposure/outcome timing and adherence/follow-up records
Further research: Research separating exposure from event-observation periods
Remaining uncertainty: Individual/arm-specific exposure, adherence/discontinuation, time at risk and outcome observation remain unverified.
Conditions for verification: For Median 164 days of use, winter period, outcome observation/adherence, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are a median 164 days/about six months separated from actual exposure/follow-up?
Application exceptions: Do not calculate 164 days as a fixed duration for everyone, total product amounts or person-time, or provide an intake schedule.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources R01

N08 · What is the exact serious-COVID-19 event/composite definition?

Current findings: The original records serious COVID-19 as one coprimary outcome. Exact severity criteria, composite components/adjudication and confirmation methods are not provided in the summary.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Composite definition/components, thresholds, testing/physician adjudication and confirmation timing remain unverified.
Reason for missing information: Composite definition/components, thresholds, testing/physician adjudication and confirmation timing remain unverified.
Required materials and conditions: Serious-outcome definition, confirmation, composite/components and thresholds
Materials to obtain first: Serious-outcome definitions, adjudication/confirmation plans and original component tables
Further research: Research specifying the serious composite and individual components
Remaining uncertainty: Composite definition/components, thresholds, testing/physician adjudication and confirmation timing remain unverified.
Conditions for verification: For Serious-outcome definition, confirmation, composite/components and thresholds, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the exact serious-COVID-19 event/composite definition?
Application exceptions: Do not newly define severity using hospitalization/death alone or add symptoms/components absent from the original.
Referenced methods: M03 §3.2.4 and M15 §15.3.1–15.3.3; Question-specific outcome adaptation is Chamgap design; M08 Table 8.2.a and M03 §3.2.4; Chamgap application; M03 §3.2.4; Chamgap interpretation boundary

Related sources R01

N09 · What are the selected serious-outcome events, RR and adjusted interval?

Current findings: Following the original endpoint order, serious outcomes were cod liver oil 121 versus placebo 101, RR 1.20 (0.87–1.65). Korean/English text describes adjusted 95% intervals and the original null result. No new RR/CI/P is calculated.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Whether events count people, first/repeated events or composite events, and the relevant denominator/model/adjustment method, remain unverified.
Reason for missing information: Whether events count people, first/repeated events or composite events, and the relevant denominator/model/adjustment method, remain unverified.
Required materials and conditions: Serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65)
Materials to obtain first: Serious-outcome events/denominators and RR/interval/analysis tables
Further research: Research specifying estimand, events/denominators and adjustment
Remaining uncertainty: Whether events count people, first/repeated events or composite events, and the relevant denominator/model/adjustment method, remain unverified.
Conditions for verification: For Serious outcomes: 121 versus 101, RR 1.20 (0.87–1.65), separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the selected serious-outcome events, RR and adjusted interval?
Application exceptions: Do not turn RR>1 into confirmed harm/a significant increase or certify the original null result as exactly zero effect/equivalence.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application; M15 §15.3.1–15.3.3; Chamgap application

Related sources R01

N10 · Is hospitalization the same as the individual effect of the serious composite?

Current findings: Original serious-event totals 121/101 and RR exist, but hospitalization components/inclusion, original events/denominators and effect/CI are not separately available. The composite result is not copied as a hospitalization result.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Hospitalization components, definition/confirmation, events/denominators/time and effect intervals remain unverified.
Reason for missing information: Hospitalization components, definition/confirmation, events/denominators/time and effect intervals remain unverified.
Required materials and conditions: Hospitalization definition/confirmation, events/denominator and composite relationship
Materials to obtain first: Original hospitalization/serious-component tables and direct definitions
Further research: A plan distinguishing the composite from individual hospitalization outcomes
Remaining uncertainty: Hospitalization components, definition/confirmation, events/denominators/time and effect intervals remain unverified.
Conditions for verification: For Hospitalization definition/confirmation, events/denominator and composite relationship, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is hospitalization the same as the individual effect of the serious composite?
Application exceptions: Do not transfer 121/101 to hospitalization counts or create zero hospitalizations or reduction/increase effects.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.4; internal extension boundaries

Related sources R01

N11 · Is death the same as the individual effect of the serious composite?

Current findings: The original summary lacks individual COVID-19/all-cause-death components, events/denominators and effect/CI. The serious-outcome RR is not transferred to a mortality RR.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Cause-specific/all-cause death, composite inclusion, events/denominators/time and estimates/CI remain unverified.
Reason for missing information: Cause-specific/all-cause death, composite inclusion, events/denominators/time and estimates/CI remain unverified.
Required materials and conditions: Death definition/period, components/individual events and denominator
Materials to obtain first: Original mortality/serious-component tables and definitions/follow-up
Further research: A plan separating serious composites from cause-specific/all-cause mortality
Remaining uncertainty: Cause-specific/all-cause death, composite inclusion, events/denominators/time and estimates/CI remain unverified.
Conditions for verification: For Death definition/period, components/individual events and denominator, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is death the same as the individual effect of the serious composite?
Application exceptions: Do not add zero deaths or sparse-event counts absent from the original, or judge null serious outcomes as mortality equivalence/no harm.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.4; internal extension boundaries

Related sources R01

N12 · Are randomized, infected and at-risk population denominators distinguished?

Current findings: Original randomization of 34,601 adults (17,278/17,323) is preserved. The exact serious-event risk denominator, conditional serious-outcome denominator among PCR-infected participants and risk subgroups are not separately available.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Outcome-specific effective denominators/infection conditions, time/subgroups and event aggregation remain unverified.
Reason for missing information: Outcome-specific effective denominators/infection conditions, time/subgroups and event aggregation remain unverified.
Required materials and conditions: 34,601/arm sizes versus serious-outcome/infected/event-risk denominators
Materials to obtain first: Randomized/infected/at-risk population flow and outcome-specific denominators
Further research: Research distinguishing populations, denominators and conditional estimands
Remaining uncertainty: Outcome-specific effective denominators/infection conditions, time/subgroups and event aggregation remain unverified.
Conditions for verification: For 34,601/arm sizes versus serious-outcome/infected/event-risk denominators, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are randomized, infected and at-risk population denominators distinguished?
Application exceptions: Do not use PCR 227/228 as serious-outcome denominators or copy full arm sizes to every component/subgroup.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M03 §3.2.1; detailed population conditions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application

Related sources R01

N13 · What is the uncertainty in serious/component events and intervals?

Current findings: Original serious events 121/101, RR 1.20, interval 0.87–1.65 and parent C0 are preserved. A large overall sample does not guarantee precision, exclusion of small differences or equivalence for each component.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Component events/denominators, estimates/CI, power/importance and sparse-event handling remain unverified.
Reason for missing information: Component events/denominators, estimates/CI, power/importance and sparse-event handling remain unverified.
Required materials and conditions: Original events/intervals, component sparsity/precision and importance
Materials to obtain first: Component-specific events/estimates/intervals and SAP
Further research: A plan distinguishing overall sample size from outcome-specific precision
Remaining uncertainty: Component events/denominators, estimates/CI, power/importance and sparse-event handling remain unverified.
Conditions for verification: For Original events/intervals, component sparsity/precision and importance, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the uncertainty in serious/component events and intervals?
Application exceptions: Do not calculate new P/CI where original intervals/P are absent or newly conclude that all important benefits/harms are excluded.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

Related sources R01

N14 · How are PCR infection, negative tests and other ARI different endpoints?

Current findings: Original PCR 227/228, RR 1.00 (0.82–1.22); negative tests 8,546/8,565, RR 1.00 (0.97–1.04); and self-reported ARI 3,964/3,834, RR 1.04 (0.97–1.11), are preserved as other-endpoint context.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Event definitions/confirmation, people/tests/repetition and denominators/models for each endpoint remain unverified.
Reason for missing information: Event definitions/confirmation, people/tests/repetition and denominators/models for each endpoint remain unverified.
Required materials and conditions: Original order of four results, related outcomes, negative tests and questionnaire ARI
Materials to obtain first: Each endpoint definition/denominator and original result tables
Further research: A plan separating infection, tests, symptoms and serious outcomes
Remaining uncertainty: Event definitions/confirmation, people/tests/repetition and denominators/models for each endpoint remain unverified.
Conditions for verification: For Original order of four results, related outcomes, negative tests and questionnaire ARI, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are PCR infection, negative tests and other ARI different endpoints?
Application exceptions: Do not turn negative tests into other confirmed infections or sum the four event counts/related claims into serious outcomes or independent trials.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.4; internal extension boundaries

Related sources R01

N15 · What was the original scope of four coprimary outcomes, fallback and adjusted intervals?

Current findings: The original describes all four coprimary outcomes as null and multiplicity control through prespecified fallback. Original adjusted 95% intervals are preserved; exact rules/adjustments/original plans remain externally unread.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Fallback allocation/success rules, interval/model adjustment and plan versions remain unverified.
Reason for missing information: Fallback allocation/success rules, interval/model adjustment and plan versions remain unverified.
Required materials and conditions: Coprimary hierarchy, multiplicity/fallback and interval adjustment
Materials to obtain first: Registration/protocol/SAP and multiplicity/interval plans
Further research: Research specifying coprimary outcomes, estimands and multiplicity
Remaining uncertainty: Fallback allocation/success rules, interval/model adjustment and plan versions remain unverified.
Conditions for verification: For Coprimary hierarchy, multiplicity/fallback and interval adjustment, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original scope of four coprimary outcomes, fallback and adjusted intervals?
Application exceptions: Do not create current prospective-specification certification from four endpoint names/original B0 quotations or arbitrarily interpret interval adjustment as baseline-covariate adjustment.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M15 §15.3.1–15.3.3; internal application

Related sources R01

N16 · What is known from the registration ID/posting/start versus current plan reading?

Current findings: Original NCT04609423 and prospective registration posted 2020-10-30 before start 2020-11-10 are preserved. External registration, protocol and SAP were not queried/read this time.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Registration content/versions, prespecified outcomes/analyses and amendment/posting records remain unread.
Reason for missing information: Registration content/versions, prespecified outcomes/analyses and amendment/posting records remain unread.
Required materials and conditions: NCT04609423, original 2020-10-30/11-10 and prospective description
Materials to obtain first: Registration versions/timing, protocol/SAP and result comparisons
Further research: Records preserving prespecified plans and amendment events
Remaining uncertainty: Registration content/versions, prespecified outcomes/analyses and amendment/posting records remain unread.
Conditions for verification: For NCT04609423, original 2020-10-30/11-10 and prospective description, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is known from the registration ID/posting/start versus current plan reading?
Application exceptions: Do not upgrade original prospective/matching quotations to current registration verification or completed plan review, or calculate date differences.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources R01

N17 · What do the original concealment/quadruple-masking quotations record?

Current findings: The original research explanation preserves quotations on hospital research-support allocation without investigator involvement and masking of participants, researchers, care, collection, assessment and analysis personnel. Actual procedures/condition recognition were not newly reviewed externally.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Allocation/concealment, maintained masking/condition comparability and baseline-balance details remain unread.
Reason for missing information: Allocation/concealment, maintained masking/condition comparability and baseline-balance details remain unread.
Required materials and conditions: Allocation without investigator involvement and masked participant/research/collection/assessment/analysis roles
Materials to obtain first: Allocation/masking/condition-recognition and baseline/protocol data
Further research: Research specifying exact allocation and masking roles
Remaining uncertainty: Allocation/concealment, maintained masking/condition comparability and baseline-balance details remain unread.
Conditions for verification: For Allocation without investigator involvement and masked participant/research/collection/assessment/analysis roles, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What do the original concealment/quadruple-masking quotations record?
Application exceptions: Do not inherit original B0/quadruple masking as current completed risk-of-bias/content review or independence certification.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources R01

N18 · Is 0.05% key-variable missingness the same as missing events/components?

Current findings: Original 34,601/17,278/17,323 and 0.05% key-variable missingness are preserved. Endpoint/serious-component omissions, risk denominators and completed withdrawal/infection follow-up are not separately available.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Missingness by arm/endpoint/component, reasons for withdrawal/discontinuation and missing-data handling remain unverified.
Reason for missing information: Missingness by arm/endpoint/component, reasons for withdrawal/discontinuation and missing-data handling remain unverified.
Required materials and conditions: Randomized/arm sizes, 0.05% key variables and outcome-specific denominators/flow
Materials to obtain first: Each flow/missingness table, SAP and collection materials
Further research: A plan distinguishing all participants/key variables from outcome-specific completeness
Remaining uncertainty: Missingness by arm/endpoint/component, reasons for withdrawal/discontinuation and missing-data handling remain unverified.
Conditions for verification: For Randomized/arm sizes, 0.05% key variables and outcome-specific denominators/flow, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Is 0.05% key-variable missingness the same as missing events/components?
Application exceptions: Do not convert 0.05% to a person count or copy it to missingness rates for every endpoint/harm.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptation is our own design; M08 §8.2.2, M15 §15.3.1; own application; M19 §19.1.2–19.2.4, M04 §4.6.3; own application

Related sources R01

N19 · What separates original ITT from adherence/infection-conditioned estimands?

Current findings: The original records an ITT quotation for all randomized participants. Adherer/infection-conditioned analyses, actual exposure and model/adjustment/missing-data details are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Estimands/analysis populations, adherence/missingness and covariate/conditional models remain unverified.
Reason for missing information: Estimands/analysis populations, adherence/missingness and covariate/conditional models remain unverified.
Required materials and conditions: All randomized adults in ITT, actual exposure/infected participants and serious-outcome estimand
Materials to obtain first: SAP, analysis populations/models and exposure/denominator materials
Further research: A plan distinguishing assigned prevention effects from serious-outcome effects among infected participants
Remaining uncertainty: Estimands/analysis populations, adherence/missingness and covariate/conditional models remain unverified.
Conditions for verification: For All randomized adults in ITT, actual exposure/infected participants and serious-outcome estimand, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates original ITT from adherence/infection-conditioned estimands?
Application exceptions: Do not repurpose a preventive assignment trial’s serious-outcome RR as treatment after infection or newly calculate absent denominators.
Referenced methods: M08 §8.2.2, M15 §15.3.1; own application; M03 §3.2.3, M08 §8.2.2–8.2.3; own application; M08 Table 8.2.a, M04 §4.6.3; own application

Related sources R01

N20 · Were baseline vitamins/conditions, vaccination and concurrent exposures verified?

Current findings: The original specifies no routine daily supplements and the winter/combination-product scope. Baseline vitamin status, comorbidities/medications, vaccination/exposure and other supplement/treatment details are absent.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Baseline/changed conditions/medications, supplements/vaccination/infection exposures and arm differences remain unverified.
Reason for missing information: Baseline/changed conditions/medications, supplements/vaccination/infection exposures and arm differences remain unverified.
Required materials and conditions: Baseline/medications, other supplements/exposures and arm differences
Materials to obtain first: Baseline/concurrent exposures and subgroup/protocol materials
Further research: Research specifying population and shared exposures
Remaining uncertainty: Baseline/changed conditions/medications, supplements/vaccination/infection exposures and arm differences remain unverified.
Conditions for verification: For Baseline/medications, other supplements/exposures and arm differences, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Were baseline vitamins/conditions, vaccination and concurrent exposures verified?
Application exceptions: Do not add deficiency diagnoses, high-dose/single-ingredient effects or infection-prevention/treatment methods without original materials.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1; detailed population conditions are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed

Related sources R01

N21 · What are the original manufacturer/institution support and outside/diagnostics-author relationships?

Current findings: The original records Orkla Health AS funding/products/placebo, Oslo hospital/university support, KBH’s outside relationships with Olympic Seafood/Amgen/Sanofi, SMU’s with Olympic Seafood, and AS/KTK employment at Age Laboratories.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Original disclosures/supporters and current design/analysis/data-access role details remain unread.
Reason for missing information: Original disclosures/supporters and current design/analysis/data-access role details remain unread.
Required materials and conditions: Orkla supply/funding, Oslo support and disclosed relationships/employees
Materials to obtain first: Original support/product-supply and author-relationship disclosures
Further research: Specify funding and research-decision/analysis roles
Remaining uncertainty: Original disclosures/supporters and current design/analysis/data-access role details remain unread.
Conditions for verification: For Orkla supply/funding, Oslo support and disclosed relationships/employees, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the original manufacturer/institution support and outside/diagnostics-author relationships?
Application exceptions: Do not combine diagnostics-company employees with manufacturer employees or turn manufacturer null reporting into independence/content-review certification or invalidation of the numbers.
Referenced methods: Chamgap’s own independence/attribution conditions. The official methodological sections used in this pilot do not guarantee every detailed item; M08 §8.1–8.2.3; internal application

Related sources R01

N22 · How are the same trial/people/composite components and related claims connected?

Current findings: The existing single evidence/citation report links four outcomes, the same people/arms/period and related claims. Composite components, tests/symptoms/events are not added as new independent trials/participants.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Individual overlap/component relationships, related reports and unique-trial/participant totals remain unverified.
Reason for missing information: Individual overlap/component relationships, related reports and unique-trial/participant totals remain unverified.
Required materials and conditions: Single Brunvoll 2022 citation, four outcomes/arms/period and overlap
Materials to obtain first: Trial/report identities and event/component/observation-unit data
Further research: Records distinguishing reports from trial families/components
Remaining uncertainty: Individual overlap/component relationships, related reports and unique-trial/participant totals remain unverified.
Conditions for verification: For Single Brunvoll 2022 citation, four outcomes/arms/period and overlap, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are the same trial/people/composite components and related claims connected?
Application exceptions: One report or four outcomes do not certify the total independent-trial count or final independence count.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources R01

N23 · What separates direct independent serious-outcome confirmation from the single-trial history?

Current findings: Parent R1/I0 and the single large manufacturer-supported trial description are preserved as history. Other independent serious-outcome source materials were not newly searched for/acquired.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Populations/products/serious-outcome definitions and overlap/independence in separate direct reports remain unverified.
Reason for missing information: Populations/products/serious-outcome definitions and overlap/independence in separate direct reports remain unverified.
Required materials and conditions: Selected product/population and independent reports of the same serious outcome
Materials to obtain first: Direct confirmation/trial-identity materials
Further research: Separate research specifying the same product/population/serious-outcome definition
Remaining uncertainty: Populations/products/serious-outcome definitions and overlap/independence in separate direct reports remain unverified.
Conditions for verification: For Selected product/population and independent reports of the same serious outcome, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates direct independent serious-outcome confirmation from the single-trial history?
Application exceptions: Do not extend the original single trial into a current claim of no worldwide studies or count related outcomes as independent replication.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources R01

N24 · What separates a null combination product from deficiency/high-dose/single-ingredient effects?

Current findings: Original counterview/ad interpretation explicitly excludes deficiency treatment, high-dose vitamin D and omega-3 alone. Combination-product results are not turned into individual-ingredient conclusions.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Direct serious-outcome data for single/other exposures or deficient/at-risk populations remain unverified.
Reason for missing information: Direct serious-outcome data for single/other exposures or deficient/at-risk populations remain unverified.
Required materials and conditions: Original product versus deficiency treatment/high-dose vitamin D/n-3 alone
Materials to obtain first: Exact ingredient/population/exposure-specific materials
Further research: A plan separating the combination product from other questions
Remaining uncertainty: Direct serious-outcome data for single/other exposures or deficient/at-risk populations remain unverified.
Conditions for verification: For Original product versus deficiency treatment/high-dose vitamin D/n-3 alone, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What separates a null combination product from deficiency/high-dose/single-ingredient effects?
Application exceptions: No new vitamin-use/deficiency-treatment guidance, product/ingredient recommendations or high-dose/treatment-replacement methods.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and testing adaptations are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed

Related sources R01

N25 · Which serious, hospitalization/death, symptom/quality-of-life outcomes can be answered?

Current findings: Original serious-event totals and infection/questionnaire ARI are different outcomes. Direct values for individual hospitalization/death, quality of life/symptom severity or treating serious disease after infection are not separately available.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Clinical components/important outcomes and direct definitions/denominators/effects/periods remain unverified.
Reason for missing information: Clinical components/important outcomes and direct definitions/denominators/effects/periods remain unverified.
Required materials and conditions: Original serious-outcome name, individual/patient-important outcomes and treatment questions
Materials to obtain first: Direct individual clinical/patient-important outcome materials
Further research: Research distinguishing prevention/serious outcomes/treatment and component-specific estimands
Remaining uncertainty: Clinical components/important outcomes and direct definitions/denominators/effects/periods remain unverified.
Conditions for verification: For Original serious-outcome name, individual/patient-important outcomes and treatment questions, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Which serious, hospitalization/death, symptom/quality-of-life outcomes can be answered?
Application exceptions: Do not extend the original prevention null result to current serious-disease treatment failure or alternative-treatment selection.
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

Related sources R01

N26 · What is the scope of summary reading, unread external materials and original links?

Current findings: The entire preserved 2972 summary was read and saved for production. PubMed URL/NCT are original source links; external content/link access, clicks and tests were not performed.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Current verification of external serious-outcome definitions/methods/results and registration/plan/disclosure details remains incomplete.
Reason for missing information: Current verification of external serious-outcome definitions/methods/results and registration/plan/disclosure details remains incomplete.
Required materials and conditions: Entire summary, abstract/full text/registration/plans/disclosures
Materials to obtain first: Acquired original materials and actual reading/addition events
Further research: Records separating summaries/identities from new acquisition
Remaining uncertainty: Current verification of external serious-outcome definitions/methods/results and registration/plan/disclosure details remains incomplete.
Conditions for verification: For Entire summary, abstract/full text/registration/plans/disclosures, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is the scope of summary reading, unread external materials and original links?
Application exceptions: Preserve absent DOI/PMCID and unread status; a URL/ID alone does not establish acquisition or access success/failure.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01

N27 · What are the bilingual text, dates/corrections, original axes/absences and history?

Current findings: Bilingual text, original evidence date 2026-08-26 and empty corrections/deliberation are preserved. Parent B/H/R1/I0/E0/B0/C0, the true large-hard-endpoint-RCT indicator, two false indicators and empty grade-override reasons remain historical context. Separate classification fields and the primary-failed/secondary-positive indicator are unrecorded.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. External original quotations/translations and detailed registration/correction comparisons were not performed this time.
Reason for missing information: External original quotations/translations and detailed registration/correction comparisons were not performed this time.
Required materials and conditions: Parent D with 34 points, languages/dates/empty values and B0 quotations/axes
Materials to obtain first: Original text, language-specific changes and date/correction events
Further research: Separate original values/absences from new updates
Remaining uncertainty: External original quotations/translations and detailed registration/correction comparisons were not performed this time.
Conditions for verification: For Parent D with 34 points, languages/dates/empty values and B0 quotations/axes, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the bilingual text, dates/corrections, original axes/absences and history?
Application exceptions: Do not inherit B0/prespecification/ITT quotations or cross-checking as current clinical-content review or independence certification.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M04 §4.5, §4.6.3; current material-conversion limits follow review scope and internal design; Chamgap’s own independence/attribution conditions. The official methodological sections used in this pilot do not guarantee every detailed item

Related sources R01

N28 · What was the original scope of harm collection and low-grade side effects?

Current findings: The original safety description states that only low-grade side effects were reported in both arms. All event definitions, collection/grading methods and serious/related-event/arm-count details are absent from the summary.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Harm collection/grading, all events and original causality/discontinuation tables remain unverified.
Reason for missing information: Harm collection/grading, all events and original causality/discontinuation tables remain unverified.
Required materials and conditions: Side-effect definitions/grading, collection/causality and arm events
Materials to obtain first: Harm plans and event/grading/discontinuation materials
Further research: Research specifying harm collection separately from efficacy
Remaining uncertainty: Harm collection/grading, all events and original causality/discontinuation tables remain unverified.
Conditions for verification: For Side-effect definitions/grading, collection/causality and arm events, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What was the original scope of harm collection and low-grade side effects?
Application exceptions: Do not turn the original low-grade-only description into zero side effects, long-term no harm or equivalent safety.
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

Related sources R01

N29 · Are side effects, serious COVID-19 and hospitalization/death categories distinguished?

Current findings: The serious-COVID-19 RR and low-grade side-effect descriptions in both arms concern different outcomes. Serious-event counts 121/101 are not transferred to product-side-effect counts.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Definitions, causality/components and denominators for efficacy events/exposure harms remain unverified.
Reason for missing information: Definitions, causality/components and denominators for efficacy events/exposure harms remain unverified.
Required materials and conditions: Exposure harms, trial-efficacy serious outcomes and other-event causality
Materials to obtain first: Efficacy/harm categories and causality/event materials
Further research: A plan separating infection severity from exposure harms
Remaining uncertainty: Definitions, causality/components and denominators for efficacy events/exposure harms remain unverified.
Conditions for verification: For Exposure harms, trial-efficacy serious outcomes and other-event causality, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are side effects, serious COVID-19 and hospitalization/death categories distinguished?
Application exceptions: Do not make new product-caused-harm or guaranteed-safety verdicts from RR 1.20 or low-grade descriptions.
Referenced methods: M19 §19.1.2–19.2.4; detailed discrimination is internally designed; Chamgap’s own interpretation boundaries. M19 principles are referenced; no official causality tool was run; M03 §3.2.4; internal extension boundaries

Related sources R01

N30 · Are overall/arm-specific harm denominators the same as key-variable missingness?

Current findings: Randomized arm sizes and key-variable missingness are described, but collection/denominators/exposure time and CI for each side effect are not separately available.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Harm denominators by arm/event/period and comparative effects/CI remain unverified.
Reason for missing information: Harm denominators by arm/event/period and comparative effects/CI remain unverified.
Required materials and conditions: 17,278/17,323, key-variable 0.05% and harm-observation populations
Materials to obtain first: Harm flow and events/denominator tables by arm
Further research: Research distinguishing efficacy analyses from harm-observation populations
Remaining uncertainty: Harm denominators by arm/event/period and comparative effects/CI remain unverified.
Conditions for verification: For 17,278/17,323, key-variable 0.05% and harm-observation populations, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are overall/arm-specific harm denominators the same as key-variable missingness?
Application exceptions: Do not copy all-participant/0.05% information into complete harm observation or calculate new incidence/differences/CI.
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; internal application; M19 §19.1.2–19.2.4; internal application

Related sources R01

N31 · What is known about harm timing, after stopping, delayed and long-term observation?

Current findings: The original has a median 164 days of use and low-grade descriptions in both arms, but no side-effect timing or post-discontinuation/delayed/longer observation details.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Exposure/event timing and direct post-study/long-term harms remain unverified.
Reason for missing information: Exposure/event timing and direct post-study/long-term harms remain unverified.
Required materials and conditions: Original median 164 days and side-effect timing/exposure/follow-up
Materials to obtain first: Exposure/harm timing and follow-up materials
Further research: A plan distinguishing timing and delayed harms
Remaining uncertainty: Exposure/event timing and direct post-study/long-term harms remain unverified.
Conditions for verification: For Original median 164 days and side-effect timing/exposure/follow-up, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What is known about harm timing, after stopping, delayed and long-term observation?
Application exceptions: Do not convert winter exposure into confirmed safety for all long-term/repeated use.
Referenced methods: M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; M19 §19.1.2–19.2.4; internal application

Related sources R01

N32 · What alternative causes involve combination product/placebo, medical history and medications?

Current findings: The original product is a combination and placebo flavour-matched corn oil. Detailed source materials attributing events to product/individual ingredients, baseline status or concurrent medications are absent.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Baseline/concurrent medications, actual exposure and event-specific causality/alternative causes remain unverified.
Reason for missing information: Baseline/concurrent medications, actual exposure and event-specific causality/alternative causes remain unverified.
Required materials and conditions: Vitamin/n-3 combination, shared exposures and event causality
Materials to obtain first: Medical history/medications/exposure and event-causality records
Further research: A harm plan distinguishing relevant exposure from alternative causes
Remaining uncertainty: Baseline/concurrent medications, actual exposure and event-specific causality/alternative causes remain unverified.
Conditions for verification: For Vitamin/n-3 combination, shared exposures and event causality, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What alternative causes involve combination product/placebo, medical history and medications?
Application exceptions: Do not add unreported ingredients/invented harms or new medication/product stopping/substitution/management instructions.
Referenced methods: M19 §19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap design; M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

Related sources R01

N33 · Are key-variable missingness, serious-outcome confirmation and harm-related stopping distinguished?

Current findings: Original 0.05% key-variable missingness and ITT are preserved. Serious-event confirmation/component omissions, side-effect-related stopping and complete harm collection are not detailed.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Event/harm omissions, arm-specific stopping reasons/causality and handling remain unverified.
Reason for missing information: Event/harm omissions, arm-specific stopping reasons/causality and handling remain unverified.
Required materials and conditions: 0.05% missingness, event confirmation/collection and stopping reasons
Materials to obtain first: Outcome/harm flow, omissions/discontinuation and SAP
Further research: A plan distinguishing missing efficacy data from harm-related stopping
Remaining uncertainty: Event/harm omissions, arm-specific stopping reasons/causality and handling remain unverified.
Conditions for verification: For 0.05% missingness, event confirmation/collection and stopping reasons, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are key-variable missingness, serious-outcome confirmation and harm-related stopping distinguished?
Application exceptions: Do not declare zero omissions in all harms/components from a small key-variable missingness rate or fill unverified events with zero.
Referenced methods: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application

Related sources R01

N34 · How do independent harm materials differ from the same trial/components/related claims?

Current findings: The current list contains this large efficacy report. Separate original harm materials were not newly searched for/acquired; the same trial/people, composite components and related claims are not counted as independent harm trials.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Independent harm-material identities, population/product/exposure and overlap remain unverified.
Reason for missing information: Independent harm-material identities, population/product/exposure and overlap remain unverified.
Required materials and conditions: Separate safety-material identities and overlap in the same people/components
Materials to obtain first: Separate harm/surveillance and event materials
Further research: Records distinguishing the same trial from independent harms
Remaining uncertainty: Independent harm-material identities, population/product/exposure and overlap remain unverified.
Conditions for verification: For Separate safety-material identities and overlap in the same people/components, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How do independent harm materials differ from the same trial/components/related claims?
Application exceptions: Do not extend the current absence of a separate slot into a claim that all external safety materials are absent.
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

Related sources R01

N35 · What are the boundaries for deficient/at-risk/vulnerable populations, current periods and long-term safety?

Current findings: The original limits scope to the tested dose/participants. It does not judge direct safety in deficient/high-risk/other-condition populations, current periods, long-term exposure or different products.
Verification status: Unverified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Required direct materials were not verified within the current summary/unread-external-material scope. Direct events, medications and long-term follow-up by population/period/exposure remain unverified.
Reason for missing information: Direct events, medications and long-term follow-up by population/period/exposure remain unverified.
Required materials and conditions: Original winter product/population versus other risks/exposures/periods
Materials to obtain first: Direct harms for at-risk/vulnerable populations and specific products/periods
Further research: Research separating population and long-term safety questions
Remaining uncertainty: Direct events, medications and long-term follow-up by population/period/exposure remain unverified.
Conditions for verification: For Original winter product/population versus other risks/exposures/periods, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: What are the boundaries for deficient/at-risk/vulnerable populations, current periods and long-term safety?
Application exceptions: No new cod-liver-oil/vitamin/product-use, infection-prevention/COVID-19 management or serious-COVID-19 treatment guidance.
Referenced methods: M19 §19.1.2–19.2.4; internal application; M03 §3.2.1; detailed population conditions are internally designed; M03 §3.2.1–3.2.4; dose/duration/effect-modification details are internally designed

Related sources R01

N36 · Are the causal scopes of null serious outcomes, other endpoints and good safety separated?

Current findings: Original null serious outcomes, null findings for the other three endpoints, low-grade side effects and parent good safety are preserved separately. The serious-outcome interval/null result is not confirmed harm, equivalence/no-harm certification or separate hospitalization/death conclusions.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Direct component/comparative harms, causality/importance and long-term precision remain unverified.
Reason for missing information: Direct component/comparative harms, causality/importance and long-term precision remain unverified.
Required materials and conditions: Serious-outcome RR/interval, efficacy/harms and parent safety
Materials to obtain first: Component-specific efficacy/harms and direct estimates/follow-up materials
Further research: A plan separating different estimands/outcomes
Remaining uncertainty: Direct component/comparative harms, causality/importance and long-term precision remain unverified.
Conditions for verification: For Serious-outcome RR/interval, efficacy/harms and parent safety, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: Are the causal scopes of null serious outcomes, other endpoints and good safety separated?
Application exceptions: Do not turn the original product null result into null effects for all vitamins/treatment replacement, guaranteed safety or a new grade.
Referenced methods: Chamgap’s own interpretation boundaries. M19 principles are referenced; no official causality tool was run; M03 §3.2.4; internal extension boundaries; M15 §15.3.1–15.3.3; internal application

Related sources R01

N37 · How are follow-up materials, historical candidates, versions and incomplete content review linked?

Current findings: Conditions were preserved/frozen before separate application. Candidate review-pending/production-eligibility labels remain historical records; current content/question-boundary review is incomplete. Zero new units and unrecorded confirmed independent totals are retained.
Verification status: Partly verified
Materials actually read: Summary read; external materials unread, access not attempted
Why unverified: Some original summary information is linked for production; this does not establish clinical verification/completed content review. Follow-up original materials, actual reading, changes, content review and independence decisions do not yet exist.
Reason for missing information: Follow-up original materials, actual reading, changes, content review and independence decisions do not yet exist.
Required materials and conditions: Preserved summary, conditions, units, denominators, components, original values and addition events
Materials to obtain first: Additional original materials, before/after values, versions and change-decision records
Further research: Research addressing direct gaps in the selected serious-COVID-19 question
Remaining uncertainty: Follow-up original materials, actual reading, changes, content review and independence decisions do not yet exist.
Conditions for verification: For Preserved summary, conditions, units, denominators, components, original values and addition events, separate original information from unverified details and boundaries on extension to infection/other respiratory outcomes, individual components/harms or current treatment.
Why this condition is needed: Distinguish original product/population, serious outcome/components/denominators and unverified scope for this question: How are follow-up materials, historical candidates, versions and incomplete content review linked?
Application exceptions: Do not invent current completed clinical-content review/publication from historical cross-checking or original production completion.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed splitting rules are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed; M04 §4.5, §4.6.3; current material-conversion limits follow review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources R01